[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 68-year-old man; 2-year progressive course; prominent sleep dysfunction with dream enactment, nocturnal stridor, REM sleep behavior disorder plus non-REM parasomnias; daytime somnolence; gait instability; mild cognitive decline; normal CSF; only mild cerebellar atrophy on MRI. This constellation is classic for anti-IgLON5 disease, a tauopathy with distinctive sleep-related phenotype and often unremarkable CSF/neuroimaging.\\nEvaluation of alternatives: Anti-Hu is typically associated with paraneoplastic sensory neuronopathy and limbic encephalitis, not a predominant parasomnia/REM behavior phenotype. Anti-Yo is linked to paraneoplastic cerebellar degeneration (more severe cerebellar atrophy and cerebellar signs, not this mixed sleep-bulbar pattern). Anti-Ma2 causes diencephalic/limbic encephalitis with hypersomnia and eye movement/brainstem signs but not this characteristic REM/non-REM parasomnia cluster. Anti-NMDA receptor encephalitis presents with acute/subacute psychiatric changes, seizures, dyskinesias, and CSF inflammation, again not matching this chronic parasomnia-predominant syndrome.\\nMain medical accuracy issues: Minor only; the description and associations are consistent with current understanding of anti-IgLON5 disease.\\nMinimal fix: Option labels are slightly redundant (e.g., “A. A) …”); standardize to a single labeling format but this does not affect medical/logical validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 68-year-old man; 2-year progressive course; prominent sleep dysfunction with dream enactment, nocturnal stridor, REM sleep behavior disorder plus non-REM parasomnias; daytime somnolence; gait instability; mild cognitive decline; normal CSF; only mild cerebellar atrophy on MRI. This constellation is classic for anti-IgLON5 disease, a tauopathy with distinctive sleep-related phenotype and often unremarkable CSF/neuroimaging.\nEvaluation of alternatives: Anti-Hu is typically associated with paraneoplastic sensory neuronopathy and limbic encephalitis, not a predominant parasomnia/REM behavior phenotype. Anti-Yo is linked to paraneoplastic cerebellar degeneration (more severe cerebellar atrophy and cerebellar signs, not this mixed sleep-bulbar pattern). Anti-Ma2 causes diencephalic/limbic encephalitis with hypersomnia and eye movement/brainstem signs but not this characteristic REM/non-REM parasomnia cluster. Anti-NMDA receptor encephalitis presents with acute/subacute psychiatric changes, seizures, dyskinesias, and CSF inflammation, again not matching this chronic parasomnia-predominant syndrome.\nMain medical accuracy issues: Minor only; the description and associations are consistent with current understanding of anti-IgLON5 disease.\nMinimal fix: Option labels are slightly redundant (e.g., “A. A) …”); standardize to a single labeling format but this does not affect medical/logical validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 32-year-old woman with irregular bleeding 18 months postpartum, mildly elevated hCG (150 mIU/mL), 4-cm intrauterine mass, biopsy showing sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, immunostaining strongly positive for hPL but negative for hCG. These findings are classic for placental site trophoblastic tumor (PSTT), which derives from implantation-site intermediate trophoblast, produces hPL with minimal hCG, and often presents months–years after pregnancy with low-level hCG.\\nAlternatives: Choriocarcinoma and invasive mole usually have very high hCG levels and strong hCG positivity on immunostain, not hPL-dominant intermediate trophoblast. Persistent hydatidiform mole also features markedly elevated hCG and villous structures, not sheets of intermediate trophoblast. Epithelioid trophoblastic tumor arises from chorionic-type intermediate trophoblast and typically shows hCG, inhibin, and p63 positivity rather than strong hPL with hCG negativity.\\nMain issues: No major logical or medical inaccuracies; the stem provides sufficient discriminating pathology and immunohistochemistry to support one best answer.\\nMinimal fix: Clarify that the lesion is at the implantation site of the previous pregnancy to further emphasize PSTT, though not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 32-year-old woman with irregular bleeding 18 months postpartum, mildly elevated hCG (150 mIU/mL), 4-cm intrauterine mass, biopsy showing sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, immunostaining strongly positive for hPL but negative for hCG. These findings are classic for placental site trophoblastic tumor (PSTT), which derives from implantation-site intermediate trophoblast, produces hPL with minimal hCG, and often presents months–years after pregnancy with low-level hCG.\nAlternatives: Choriocarcinoma and invasive mole usually have very high hCG levels and strong hCG positivity on immunostain, not hPL-dominant intermediate trophoblast. Persistent hydatidiform mole also features markedly elevated hCG and villous structures, not sheets of intermediate trophoblast. Epithelioid trophoblastic tumor arises from chorionic-type intermediate trophoblast and typically shows hCG, inhibin, and p63 positivity rather than strong hPL with hCG negativity.\nMain issues: No major logical or medical inaccuracies; the stem provides sufficient discriminating pathology and immunohistochemistry to support one best answer.\nMinimal fix: Clarify that the lesion is at the implantation site of the previous pregnancy to further emphasize PSTT, though not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 18-year-old with genetically confirmed Danon disease, severe HCM (septal thickness 28 mm), WPW pattern, multiple (three) accessory pathways on EP study, recurrent syncope, and persistent pre-excited atrial fibrillation despite maximal medical therapy. Danon disease is known for rapidly progressive cardiomyopathy, high arrhythmic risk, and poor prognosis; EP ablation success is limited and recurrence common. In this context, early referral for heart transplantation evaluation is the most appropriate next management step, matching option D.\\nOther options: Flecainide (A) may be used for WPW but here is only palliative and does not address the underlying rapidly progressive, high-risk phenotype. Ablation of all accessory pathways (B) is often unsuccessful/temporary in Danon disease and does not address progressive cardiomyopathy. Increasing beta-blocker (C) is inappropriate and can worsen pre-excited AF. Dual-chamber pacemaker (E) does not treat the life‑threatening substrate.\\nMedical accuracy: The pathophysiology, prognosis, and management priorities are current and consistent with expert consensus for Danon disease with severe cardiomyopathy and arrhythmias.\\nMinimal fix: Explicitly state that prior ablation has already been attempted or is deemed noncurative to further justify moving directly to transplant evaluation.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 18-year-old with genetically confirmed Danon disease, severe HCM (septal thickness 28 mm), WPW pattern, multiple (three) accessory pathways on EP study, recurrent syncope, and persistent pre-excited atrial fibrillation despite maximal medical therapy. Danon disease is known for rapidly progressive cardiomyopathy, high arrhythmic risk, and poor prognosis; EP ablation success is limited and recurrence common. In this context, early referral for heart transplantation evaluation is the most appropriate next management step, matching option D.\nOther options: Flecainide (A) may be used for WPW but here is only palliative and does not address the underlying rapidly progressive, high-risk phenotype. Ablation of all accessory pathways (B) is often unsuccessful/temporary in Danon disease and does not address progressive cardiomyopathy. Increasing beta-blocker (C) is inappropriate and can worsen pre-excited AF. Dual-chamber pacemaker (E) does not treat the life‑threatening substrate.\nMedical accuracy: The pathophysiology, prognosis, and management priorities are current and consistent with expert consensus for Danon disease with severe cardiomyopathy and arrhythmias.\nMinimal fix: Explicitly state that prior ablation has already been attempted or is deemed noncurative to further justify moving directly to transplant evaluation.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-term natalizumab use (30 months), high JCV antibody index (2.8), subacute cognitive decline, MRI with non-enhancing subcortical white-matter lesions without mass effect, and positive CSF JCV PCR – all classic for natalizumab-associated PML. In proven natalizumab-related PML, the management priority is rapid removal of the drug via plasma exchange to accelerate immune reconstitution and improve survival.\\nOption C (immediate plasma exchange) fits current standard care: natalizumab discontinuation plus urgent PLEX to clear the drug. A (continue natalizumab) and B (switch to ocrelizumab) would worsen/immunosuppress further and are contraindicated. D (mirtazapine) and E (mefloquine) have only investigational/weak data and are not survival-critical measures.\\nMinor issue: The explanation states PLEX prevents IRIS; more accurately, PLEX accelerates immune reconstitution and can precipitate IRIS, which is managed separately, but overall improves survival. This is a nuance, not enough to mislead on the key teaching point.\\nMinimal fix: Revise the explanation to state “to rapidly clear natalizumab, accelerate immune reconstitution (accepting IRIS risk), and improve survival” rather than “preventing IRIS.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-term natalizumab use (30 months), high JCV antibody index (2.8), subacute cognitive decline, MRI with non-enhancing subcortical white-matter lesions without mass effect, and positive CSF JCV PCR – all classic for natalizumab-associated PML. In proven natalizumab-related PML, the management priority is rapid removal of the drug via plasma exchange to accelerate immune reconstitution and improve survival.\nOption C (immediate plasma exchange) fits current standard care: natalizumab discontinuation plus urgent PLEX to clear the drug. A (continue natalizumab) and B (switch to ocrelizumab) would worsen/immunosuppress further and are contraindicated. D (mirtazapine) and E (mefloquine) have only investigational/weak data and are not survival-critical measures.\nMinor issue: The explanation states PLEX prevents IRIS; more accurately, PLEX accelerates immune reconstitution and can precipitate IRIS, which is managed separately, but overall improves survival. This is a nuance, not enough to mislead on the key teaching point.\nMinimal fix: Revise the explanation to state “to rapidly clear natalizumab, accelerate immune reconstitution (accepting IRIS risk), and improve survival” rather than “preventing IRIS.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle-aged man with chronic, non–histamine-responsive urticarial rash, recurrent fevers, debilitating bone pain, markedly elevated ESR/CRP, and monoclonal IgM κ paraprotein. This classic constellation is diagnostic for Schnitzler syndrome, a late-onset autoinflammatory syndrome associated with an IgM monoclonal gammopathy and systemic inflammation. Pathophysiologically, Schnitzler syndrome is driven by NLRP3 inflammasome activation leading to excess IL-1β, and IL‑1 blockade (e.g., anakinra, canakinumab) is the established first-line therapy that rapidly controls symptoms.\\nIL‑1 (option A) is therefore the primary therapeutic cytokine target. IL‑6 and TNF‑α can be elevated but are downstream/inflammatory markers rather than the main driver. IL‑17 and interferon‑γ are not central to this condition’s mechanism or treatment. The stem contains sufficient, specific features to uniquely identify Schnitzler syndrome and distinguish IL‑1 from other cytokines.\\nMain medical accuracy issues: None; description and explanation are current and consistent with accepted literature.\\nMinimal fix: Remove duplicated letters in options (e.g., list as “A. Interleukin-1”) to standardize formatting; content otherwise already unambiguous and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle-aged man with chronic, non–histamine-responsive urticarial rash, recurrent fevers, debilitating bone pain, markedly elevated ESR/CRP, and monoclonal IgM κ paraprotein. This classic constellation is diagnostic for Schnitzler syndrome, a late-onset autoinflammatory syndrome associated with an IgM monoclonal gammopathy and systemic inflammation. Pathophysiologically, Schnitzler syndrome is driven by NLRP3 inflammasome activation leading to excess IL-1β, and IL‑1 blockade (e.g., anakinra, canakinumab) is the established first-line therapy that rapidly controls symptoms.\nIL‑1 (option A) is therefore the primary therapeutic cytokine target. IL‑6 and TNF‑α can be elevated but are downstream/inflammatory markers rather than the main driver. IL‑17 and interferon‑γ are not central to this condition’s mechanism or treatment. The stem contains sufficient, specific features to uniquely identify Schnitzler syndrome and distinguish IL‑1 from other cytokines.\nMain medical accuracy issues: None; description and explanation are current and consistent with accepted literature.\nMinimal fix: Remove duplicated letters in options (e.g., list as “A. Interleukin-1”) to standardize formatting; content otherwise already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young adult with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, cerebellar ataxia, elevated cholestanol, and confirmed cerebrotendinous xanthomatosis (CYP27A1 deficiency). Question asks for the treatment that halts neurologic progression. In CTX, chenodeoxycholic acid replacement is standard therapy; it normalizes bile acid synthesis, suppresses abnormal cholestanol production, and has evidence for stabilizing/improving neurologic symptoms.\\nEvaluation of alternatives: High‑intensity statins, ezetimibe, and LDL apheresis reduce circulating LDL/cholesterol but do not adequately address CNS cholestanol or the underlying bile acid defect, and are not established to halt neurologic progression in CTX. Coenzyme Q10 targets mitochondrial disorders; no evidence it modifies CTX course. Thus B is uniquely correct.\\nMain medical accuracy issues: Minor mechanistic oversimplification—CDCA works primarily via feedback inhibition of cholesterol 7α‑hydroxylase and bile acid pathway normalization, but this is directionally correct and not misleading.\\nMinimal fix: Option labels should omit duplicated letters (“A. A) …”) for clarity; otherwise stem, key, and explanation are appropriate and current with standard teaching on CTX management.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young adult with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, cerebellar ataxia, elevated cholestanol, and confirmed cerebrotendinous xanthomatosis (CYP27A1 deficiency). Question asks for the treatment that halts neurologic progression. In CTX, chenodeoxycholic acid replacement is standard therapy; it normalizes bile acid synthesis, suppresses abnormal cholestanol production, and has evidence for stabilizing/improving neurologic symptoms.\nEvaluation of alternatives: High‑intensity statins, ezetimibe, and LDL apheresis reduce circulating LDL/cholesterol but do not adequately address CNS cholestanol or the underlying bile acid defect, and are not established to halt neurologic progression in CTX. Coenzyme Q10 targets mitochondrial disorders; no evidence it modifies CTX course. Thus B is uniquely correct.\nMain medical accuracy issues: Minor mechanistic oversimplification—CDCA works primarily via feedback inhibition of cholesterol 7α‑hydroxylase and bile acid pathway normalization, but this is directionally correct and not misleading.\nMinimal fix: Option labels should omit duplicated letters (“A. A) …”) for clarity; otherwise stem, key, and explanation are appropriate and current with standard teaching on CTX management.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 16-year-old girl; cyclic pelvic pain with menses; normal menstrual bleeding; imaging shows didelphic uterus; 5-cm right hematocolpos; normal left uterine horn; right renal agenesis. This classic triad (uterus didelphys, obstructed hemivagina with hematocolpos, ipsilateral renal agenesis) uniquely indicates OHVIRA syndrome.\\nOther options: MRKH syndrome would present with primary amenorrhea and uterine/vaginal agenesis, not a didelphic uterus with normal menses. Complete androgen insensitivity involves 46,XY karyotype, absent Müllerian structures, and typically inguinal or labial testes, not uterus didelphys or hematocolpos. A transverse vaginal septum and imperforate hymen both occur with a single, normal uterus and typically normal kidneys, and would not explain a didelphic uterus plus unilateral renal agenesis.\\nNo major logical issues: the stem clearly supports a single best diagnosis, and the key matches. Medical content is accurate and consistent with recognized descriptions of OHVIRA. \\nMinimal fix: None required; item is already clear and accurate. Option formatting could be standardized (remove duplicated letters like “A)” in the text), but this does not affect medical or logical validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 16-year-old girl; cyclic pelvic pain with menses; normal menstrual bleeding; imaging shows didelphic uterus; 5-cm right hematocolpos; normal left uterine horn; right renal agenesis. This classic triad (uterus didelphys, obstructed hemivagina with hematocolpos, ipsilateral renal agenesis) uniquely indicates OHVIRA syndrome.\nOther options: MRKH syndrome would present with primary amenorrhea and uterine/vaginal agenesis, not a didelphic uterus with normal menses. Complete androgen insensitivity involves 46,XY karyotype, absent Müllerian structures, and typically inguinal or labial testes, not uterus didelphys or hematocolpos. A transverse vaginal septum and imperforate hymen both occur with a single, normal uterus and typically normal kidneys, and would not explain a didelphic uterus plus unilateral renal agenesis.\nNo major logical issues: the stem clearly supports a single best diagnosis, and the key matches. Medical content is accurate and consistent with recognized descriptions of OHVIRA. \nMinimal fix: None required; item is already clear and accurate. Option formatting could be standardized (remove duplicated letters like “A)” in the text), but this does not affect medical or logical validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer\\nKey stem clues: HM3 LVAD patient with acute hemolysis (very high LDH, plasma free Hgb), dark urine, symptoms, increased power with spikes, and TTE evidence of inflow cannula obstruction → classic for clinically significant LVAD pump thrombosis with suspected inflow obstruction.\\nMain logical/clinical issues: The keyed answer (D: intrapump alteplase 10 mg via percutaneous catheter) reflects a center‑specific or investigational strategy, not an established, guideline-endorsed standard of care for HM3 thrombosis. In a hemodynamically stable but clearly thrombosed pump with obstructed inflow, most accepted immediate management is IV unfractionated heparin, urgent imaging/CT/transesophageal echo, and team evaluation; direct intrapump tPA dosing regimen (10 mg) is not standard or broadly evidence-based. Option B (IV heparin) is closer to broadly accepted initial management but is not clearly written as such (no mention of diagnostic/consult steps), while E (emergent pump exchange) is too aggressive without hemodynamic collapse or failed lysis. Because none of the given options represents a clearly consensus “most appropriate immediate management,” no answer is fully defensible.\\nMinimal fix: Replace D with “Initiate IV heparin and urgently consult LVAD/cardiac surgery team for consideration of catheter-directed thrombolysis vs surgical pump exchange,” and key that choice.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer\nKey stem clues: HM3 LVAD patient with acute hemolysis (very high LDH, plasma free Hgb), dark urine, symptoms, increased power with spikes, and TTE evidence of inflow cannula obstruction → classic for clinically significant LVAD pump thrombosis with suspected inflow obstruction.\nMain logical/clinical issues: The keyed answer (D: intrapump alteplase 10 mg via percutaneous catheter) reflects a center‑specific or investigational strategy, not an established, guideline-endorsed standard of care for HM3 thrombosis. In a hemodynamically stable but clearly thrombosed pump with obstructed inflow, most accepted immediate management is IV unfractionated heparin, urgent imaging/CT/transesophageal echo, and team evaluation; direct intrapump tPA dosing regimen (10 mg) is not standard or broadly evidence-based. Option B (IV heparin) is closer to broadly accepted initial management but is not clearly written as such (no mention of diagnostic/consult steps), while E (emergent pump exchange) is too aggressive without hemodynamic collapse or failed lysis. Because none of the given options represents a clearly consensus “most appropriate immediate management,” no answer is fully defensible.\nMinimal fix: Replace D with “Initiate IV heparin and urgently consult LVAD/cardiac surgery team for consideration of catheter-directed thrombolysis vs surgical pump exchange,” and key that choice.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 55-year-old, immunocompetent; occupational soil exposure (gardener); subacute (3 weeks) progressive neurologic deficits (headache, focal seizures, hemiparesis); MRI with multiple ring-enhancing lesions and edema; CSF with lymphocytic pleocytosis; all bacterial, fungal, mycobacterial cultures negative. These findings in an immunocompetent person with soil exposure strongly suggest granulomatous amoebic encephalitis due to Balamuthia (or Acanthamoeba), for which miltefosine-based, albendazole-containing regimens are the empiric recommendation.\\n\\nChoice B (albendazole + miltefosine) aligns with current case-based and CDC-guided regimens for Balamuthia/Acanthamoeba GAE and fits the exposure and imaging pattern better than fungal, bacterial, or viral therapies.\\n\\nOther options: A (liposomal amphotericin B) – more aligned with certain fungal infections/Naegleria, but soil exposure and subacute course with negative fungal cultures make this less likely. C (vanc + ceftriaxone + dexamethasone) – would fit acute bacterial meningitis, not subacute ring lesions with negative cultures. D (ganciclovir + foscarnet) – CMV encephalitis in immunocompromised, not this case. E (voriconazole) – used for aspergillosis and other fungi, again unlikely with negative fungal cultures.\\n\\nMain medical/logical issues: Minor—GAE therapy is not fully standardized, but regimen is reasonable.\\n\\nMinimal fix: Explicitly mention that amoebic PCR or biopsy is pending but suspected based on soil exposure and negative cultures to tighten the inference.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 55-year-old, immunocompetent; occupational soil exposure (gardener); subacute (3 weeks) progressive neurologic deficits (headache, focal seizures, hemiparesis); MRI with multiple ring-enhancing lesions and edema; CSF with lymphocytic pleocytosis; all bacterial, fungal, mycobacterial cultures negative. These findings in an immunocompetent person with soil exposure strongly suggest granulomatous amoebic encephalitis due to Balamuthia (or Acanthamoeba), for which miltefosine-based, albendazole-containing regimens are the empiric recommendation.\n\nChoice B (albendazole + miltefosine) aligns with current case-based and CDC-guided regimens for Balamuthia/Acanthamoeba GAE and fits the exposure and imaging pattern better than fungal, bacterial, or viral therapies.\n\nOther options: A (liposomal amphotericin B) – more aligned with certain fungal infections/Naegleria, but soil exposure and subacute course with negative fungal cultures make this less likely. C (vanc + ceftriaxone + dexamethasone) – would fit acute bacterial meningitis, not subacute ring lesions with negative cultures. D (ganciclovir + foscarnet) – CMV encephalitis in immunocompromised, not this case. E (voriconazole) – used for aspergillosis and other fungi, again unlikely with negative fungal cultures.\n\nMain medical/logical issues: Minor—GAE therapy is not fully standardized, but regimen is reasonable.\n\nMinimal fix: Explicitly mention that amoebic PCR or biopsy is pending but suspected based on soil exposure and negative cultures to tighten the inference.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Child (8 years) with recurrent fevers, livedo racemosa, recurrent lacunar strokes, vasculitic neuropathy, hypogammaglobulinemia pattern (low IgM, elevated IgA), negative ANCA, and confirmed biallelic loss-of-function ADA2 mutations. This clearly establishes DADA2 (deficiency of adenosine deaminase 2), a monogenic vasculitis with TNF-driven pathophysiology. The question asks for the biologic therapy most effective for this condition.\\n\\nEtanercept (TNF-α inhibitor) is well-described as highly effective and often first-line for DADA2, frequently inducing remission and preventing further strokes. High-dose glucocorticoids and cyclophosphamide can give partial/temporary control but are significantly less effective and not optimal long-term. Anakinra (IL-1 blockade) has only variable benefit; rituximab is not expected to work because the disease is not primarily B-cell mediated. Thus, only C is clearly best.\\n\\nMedical accuracy is strong and consistent with current understanding and case series of DADA2 management.\\n\\nMinimal fix: Remove “High-dose systemic glucocorticoids” from being labeled a “biologic therapy” (e.g., phrase the stem as “Which treatment, among the following, is most effective…” or replace A with another biologic such as infliximab) to maintain categorical consistency in options.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Child (8 years) with recurrent fevers, livedo racemosa, recurrent lacunar strokes, vasculitic neuropathy, hypogammaglobulinemia pattern (low IgM, elevated IgA), negative ANCA, and confirmed biallelic loss-of-function ADA2 mutations. This clearly establishes DADA2 (deficiency of adenosine deaminase 2), a monogenic vasculitis with TNF-driven pathophysiology. The question asks for the biologic therapy most effective for this condition.\n\nEtanercept (TNF-α inhibitor) is well-described as highly effective and often first-line for DADA2, frequently inducing remission and preventing further strokes. High-dose glucocorticoids and cyclophosphamide can give partial/temporary control but are significantly less effective and not optimal long-term. Anakinra (IL-1 blockade) has only variable benefit; rituximab is not expected to work because the disease is not primarily B-cell mediated. Thus, only C is clearly best.\n\nMedical accuracy is strong and consistent with current understanding and case series of DADA2 management.\n\nMinimal fix: Remove “High-dose systemic glucocorticoids” from being labeled a “biologic therapy” (e.g., phrase the stem as “Which treatment, among the following, is most effective…” or replace A with another biologic such as infliximab) to maintain categorical consistency in options.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]